Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study Danila CoradiniCinzia PellizzaroMaria Grazia Daidone OriginalPaper Pages: 207 - 217
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice Heleen A. BardelmeijerMariƫt OuwehandOlaf van Tellingen OriginalPaper Pages: 219 - 229
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent Gary P. WilkinsonJames P. TaylorPaul M. Loadman OriginalPaper Pages: 231 - 240
In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug Esther F. A. BrandonRolf W. SparidansJan H. M. Schellens OriginalPaper Pages: 241 - 251
A novel mammalian cell-based approach for the discovery of anticancer drugs with reduced cytotoxicity on non-dividing cells Valeria Gonzalez-NicoliniCornelia FuxMartin Fussenegger OriginalPaper Pages: 253 - 262
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers K. GelmonH. HirteE. Eisenhauer OriginalPaper Pages: 263 - 275
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma Thomas E. HutsonRam GanapathiRonald M. Bukowski OriginalPaper Pages: 277 - 284
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients Alex SparreboomSharon MarshHoward L. McLeod OriginalPaper Pages: 285 - 289
Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC) Valerie IsraelScott T. TagawaDerek Raghavan OriginalPaper Pages: 291 - 297
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer Eardie A. Curry IIIDaryl J. MurryChristopher J. Sweeney OriginalPaper Pages: 299 - 305
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer Paulo M. HoffEverardo D. SaadJames L. Abbruzzese OriginalPaper Pages: 307 - 313
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma Susan Burdette-RadouxRichard G. TozerElizabeth A. Eisenhauer OriginalPaper Pages: 315 - 322
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium Hedy L. KindlerAnjali AvadhaniEverett E. Vokes OriginalPaper Pages: 323 - 327
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors M.J.A. de JongeJ.P. DrozP. Fumoleau OriginalPaper Pages: 329 - 333
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study Robert P. WhiteheadJacqueline K. BenedettiJohn S. Macdonald OriginalPaper Pages: 335 - 341
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group Russell J. SchilderJohn A. BlessingPeter G. Rose OriginalPaper Pages: 343 - 349